By pharmacologically inhibiting IRE1α using the chemical STF, we found that the inhibition of IRE1α activity is able to reverse HFD-induced insulin resistance and comorbidities, indicating that the increased IRE1α activity is an important contributor to obesity-associated insulin resistance. The gene discussed is ERN1; the disease is obesity disorder.